Home  »  Business   »  GreenLight Biosciences Holdings (NASDAQ:GRNA): Buy...

GreenLight Biosciences Holdings (NASDAQ:GRNA): Buy, Sell Or Hold At $1.27?

In last trading session, GreenLight Biosciences Holdings (NASDAQ:GRNA) saw 0.42 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.27 trading at $0.07 or 5.83% at ring of the bell on the day assigns it a market valuation of $224.56M. That closing price of GRNA’s stock is at a discount of -1144.09% from its 52-week high price of $15.80 and is indicating a premium of 14.17% from its 52-week low price of $1.09. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 459.97K if we extend that period to 3-months.

GreenLight Biosciences Holdings (NASDAQ:GRNA) trade information

Upright in the green during last session for gaining 5.83%, in the last five days GRNA remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $1.27 price level, adding 27.01% to its value on the day. GreenLight Biosciences Holdings’s shares saw a change of -87.20% in year-to-date performance and have moved -23.49% in past 5-day. GreenLight Biosciences Holdings (NASDAQ:GRNA) showed a performance of -33.85% in past 30-days. Number of shares sold short was 2.25 million shares which calculate 3.74 days to cover the short interests.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


GRNA Dividends

GreenLight Biosciences Holdings is more likely to be releasing its next quarterly report on August 15 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

GreenLight Biosciences Holdings (NASDAQ:GRNA)’s Major holders

Insiders are in possession of 45.42% of company’s total shares while institution are holding 23.34 percent of that, with stock having share float percentage of 42.76%. Investors also watch the number of corporate investors in a company very closely, which is 23.34% institutions for GreenLight Biosciences Holdings that are currently holding shares of the company. Cormorant Asset Management, LP is the top institutional holder at GRNA for having 6.96 million shares of worth $15.38 million. And as of Jun 29, 2022, it was holding 4.60% of the company’s outstanding shares.

The second largest institutional holder is VK Services, LLC, which was holding about 5.22 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 3.45% of outstanding shares, having a total worth of $11.54 million.

On the other hand, iShares Russell 2000 ETF and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 1.32 million shares of worth $3.07 million or 0.87% of the total outstanding shares. The later fund manager was in possession of 0.81 million shares on Jun 29, 2022, making its stake of worth around $1.79 million in the company or a holder of 0.54% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts